Foresite, Arch fuel $92M round for Interline Therapeutics, a biotech taking aim at protein communities
We often think of proteins as isolated targets for drugs, says Zach Sweeney, Ph.D., a biopharma veteran who most recently was chief scientific officer at Denali Therapeutics. But it's more complicated than that. Enter Interline Therapeutics, which launches with $92 million to develop drugs that alter protein communities to treat disease.